Loading InvisibleSignal...

Pediatric Invisible Illness

Children and adolescents with invisible conditions face unique diagnostic, educational, and psychosocial challenges. This dashboard explores pediatric prevalence, age-specific symptom patterns, school accommodation frameworks, family impact, and strategies for advocacy and transition to adult care.

Pediatric Lyme

~476K

US cases/year, 25% of all Lyme diagnoses

Avg Diagnostic Delay

3.2 yrs

Average time to correct diagnosis in children

School Days Lost

25+

days/year for 40% of affected children

Misdiagnosis Rate

60%

initially misdiagnosed as behavioral/psych

Prevalence of Invisible Illnesses in Children

Invisible illnesses in the pediatric population are significantly underdiagnosed. Many conditions peak during critical developmental windows, and symptoms are frequently attributed to normal childhood behavior, growing pains, or anxiety.

Pediatric Lyme Disease

~476,0005-14 peak incidence

Children represent ~25% of all Lyme cases

Children ages 5-14 have the highest incidence of Lyme disease of any age group. Erythema migrans rash is present in only ~70% of pediatric cases, complicating early diagnosis. Post-treatment Lyme disease syndrome affects 10-20% of treated children.

Juvenile Fibromyalgia

~1-6%13-15 peak onset

Prevalence 1.2-6.2% in school-age children

Juvenile primary fibromyalgia syndrome (JPFS) affects predominantly adolescent girls (3:1 ratio). Widespread pain, fatigue, sleep disturbance, and cognitive difficulties mirror adult presentation but are frequently attributed to growing pains or school avoidance.

Pediatric ME/CFS

~0.1-0.5%10-17 peak onset

Estimated 25,000-100,000 US children affected

Pediatric ME/CFS is one of the most common causes of prolonged school absence. Post-exertional malaise is the hallmark symptom. Onset frequently follows viral infection (EBV, influenza, COVID-19). Average diagnostic delay is 2-5 years in children.

PANS/PANDAS

~1 in 2003-12 typical onset

Acute-onset OCD/tics following infection

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS) and the broader PANS category present with sudden-onset OCD, anxiety, emotional lability, and cognitive regression. Autoimmune-mediated basal ganglia inflammation is the suspected mechanism.

Pediatric POTS

~1-3%12-17 peak onset

Significant increase post-COVID-19 pandemic

Postural Orthostatic Tachycardia Syndrome in adolescents causes dizziness, fatigue, brain fog, and exercise intolerance. Often triggered by viral illness, growth spurts, or concussion. 85% are female. Average diagnostic delay is 2-4 years. Many are misdiagnosed with anxiety.

Primary Quality-of-Life Impact Areas

Distribution of the most significant quality-of-life impacts reported by families of children with invisible illnesses, based on pediatric quality-of-life inventories.

Pediatric Invisible Illness Diagnoses by Age Group

Relative diagnosis frequency per 100,000 children in each age group. Lyme disease peaks in early childhood (5-9), while POTS and fibromyalgia become more prevalent in adolescence.

Data Sources (6)

American Academy of Pediatrics (AAP). Lyme Disease in Children: Clinical Guidelines. 2024.
Centers for Disease Control and Prevention (CDC). Pediatric Lyme Disease Surveillance Data. 2024.
NIH National Institute of Child Health and Human Development (NICHD). Pediatric ME/CFS Research Program. 2023.
American Academy of Pediatrics (AAP). PANS/PANDAS Diagnostic Guidelines. 2023.
NIH National Institute of Child Health and Human Development (NICHD). Juvenile Fibromyalgia Prevalence Study. 2024.
U.S. Department of Education. Section 504 and IDEA Guidance for Chronic Illness. 2024.

Explore Related Modules

Pediatric Guide

Children & invisible illness

Family Resources

Pediatric & family support

Age & Gender

Demographic disparity analysis

Demographics

Prevalence disparities

Caregiver Support

Burnout prevention & resources

Education Library

Evidence-based learning resources